HWHG(SH:600079) Zheng Quan Shi Bao Wang·2026-01-12 08:26Core Viewpoint - ST Renfu (600079) has received approval from the National Medical Products Administration for the drug registration application of Nalbuphine Hydrochloride Injection, indicating a significant step in expanding its product offerings in the pain management sector [1] Group 1: Product Approval - The approval notification for Nalbuphine Hydrochloride Injection was issued on January 12, 2023, by the National Medical Products Administration [1] - Nalbuphine Hydrochloride Injection was initially approved for market in 2013, with indications for use as an analgesic during anesthesia induction and postoperative pain management [1] - In September 2022, the company obtained clinical trial approval for the use of Nalbuphine Hydrochloride in intensive care unit (ICU) pain management [1]